Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
FDA advisers narrowly back accelerated approval of Sarepta gene therapy
07:13pm, Friday, 12'th May 2023
U.S. Food and Drug Administration advisers voted 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.'s gene therapy for Duchenne muscular dystrophy despite quest
Sarepta Therapeutics stock halted premarket ahead of FDA panel meeting on new Duchenne muscular dystrophy treatment
07:44am, Friday, 12'th May 2023
Sarepta Therapeutics Inc. stock SRPT, -0.88% was halted premarket Friday, ahead of a meeting of a Food and Drug Administration advisory panel to discuss the company's SRP-9001 gene therapy for the rar
Why Sarepta Therapeutics Stock Faded This Week
02:23pm, Thursday, 11'th May 2023
Sarepta Therapeutics is heading into an important expert panel review this Friday for its Duchenne muscular dystrophy gene therapy candidate. The FDA's briefing documents ahead of this meeting raised
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
12:55pm, Wednesday, 03'rd May 2023
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript
08:52pm, Tuesday, 02'nd May 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Mary Jenkins – Associate Director-Investor Relations Doug Ingram – President
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
07:09pm, Tuesday, 02'nd May 2023
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy
01:42pm, Friday, 14'th Apr 2023
Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.
Sarepta shares tumble as concerns mount over FDA approval on gene therapy
03:44pm, Thursday, 13'th Apr 2023
CNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.
Sarepta Therapeutics Tumbles on Gene Therapy Drama
11:03am, Thursday, 13'th Apr 2023
A report raised questions about the chances for approval of the company's gene therapy to treat Duchenne muscular dystrophy.
Sarepta Therapeutics shares fall as report says FDA almost rejected its gene therapy
10:26am, Thursday, 13'th Apr 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares took a beating Thursday as Stat News reported that reviewers at the US Food and Drug Administration (FDA) were leaning toward rejecting a closely watched
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
10:11am, Thursday, 13'th Apr 2023
Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday that sent SRPT stock into a dive. The post Sarepta Tumbles As Report Of I
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
09:29am, Thursday, 13'th Apr 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. According to these reports, regulators at the FDA
2 Top Growth Stocks That Could Soar This Spring
05:39am, Thursday, 06'th Apr 2023
An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could exte
Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says Analyst
12:15pm, Tuesday, 04'th Apr 2023
Citi analyst Neena Bitritto-Garg initiates coverage on shares of Sarepta with a Buy rating.
